10x Genomics Inc - Ordinary Shares - Class A Forecast, price target & analysts
Why the stock moved Beta
10x Genomics Inc - Ordinary Shares - Class A Target price 2026 - Analyst rating & recommendation
10x Genomics Inc - Ordinary Shares - Class A Classifications & Recommendation
10x Genomics Inc - Ordinary Shares - Class A Price Target
| Target Price | $51.00 |
| Price | $84.11 |
| Deviation |
39.37%
register free of charge
|
| Number of Estimates | 15 |
|
15 Analysts have issued a price target 10x Genomics Inc - Ordinary Shares - Class A 2027 .
The average 10x Genomics Inc - Ordinary Shares - Class A target price is $51.00.
This is
39.37%
register free of charge
$68.25
18.86%
register free of charge
$20.20
75.98%
register free of charge
|
|
| A rating was issued by 20 analysts: 9 Analysts recommend 10x Genomics Inc - Ordinary Shares - Class A to buy, 11 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the 10x Genomics Inc - Ordinary Shares - Class A stock has an average upside potential 2027 of
39.37%
register free of charge
|
Sales and Margin forecast 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Million $ | 642.82 | 626.16 |
| 5.24% | 2.59% | |
| EBITDA Margin | -9.86% | -10.67% |
| 61.53% | 8.20% | |
| Net Margin | -6.77% | -15.63% |
| 77.35% | 130.76% |
17 Analysts have issued a sales forecast 10x Genomics Inc - Ordinary Shares - Class A 2026 . The average 10x Genomics Inc - Ordinary Shares - Class A sales estimate is
This results in the following potential growth metrics:
14 Analysts have issued an 10x Genomics Inc - Ordinary Shares - Class A EBITDA forecast 2026. The average 10x Genomics Inc - Ordinary Shares - Class A EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
16 10x Genomics Inc - Ordinary Shares - Class A Analysts have issued a net profit forecast 2026. The average 10x Genomics Inc - Ordinary Shares - Class A net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -0.35 | -0.75 |
| 76.97% | 114.29% | |
| P/E | negative | |
| EV/Sales | 14.85 |
16 Analysts have issued a 10x Genomics Inc - Ordinary Shares - Class A forecast for earnings per share. The average 10x Genomics Inc - Ordinary Shares - Class A EPS is
This results in the following potential growth metrics and future valuations:
10x Genomics Inc - Ordinary Shares - Class A...
Current 10x Genomics Inc - Ordinary Shares - Class A Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| UBS |
Locked
➜
Locked
|
Locked | Sep 09 2026 |
| RBC Capital |
Locked
➜
Locked
|
Locked | Sep 01 2026 |
| Stephens & Co. |
Locked
➜
Locked
|
Locked | Aug 12 2026 |
| Piper Sandler |
Locked
➜
Locked
|
Locked | Aug 10 2026 |
| Canaccord Genuity |
Locked
➜
Locked
|
Locked | Aug 10 2026 |
| Citigroup |
Locked
➜
Locked
|
Locked | Aug 07 2026 |
| Morgan Stanley |
Locked
➜
Locked
|
Locked | Aug 07 2026 |
| Analyst Rating | Date |
|---|---|
|
Locked
UBS:
Locked
➜
Locked
|
Sep 09 2026 |
|
Locked
RBC Capital:
Locked
➜
Locked
|
Sep 01 2026 |
|
Locked
Stephens & Co.:
Locked
➜
Locked
|
Aug 12 2026 |
|
Locked
Piper Sandler:
Locked
➜
Locked
|
Aug 10 2026 |
|
Locked
Canaccord Genuity:
Locked
➜
Locked
|
Aug 10 2026 |
|
Locked
Citigroup:
Locked
➜
Locked
|
Aug 07 2026 |
|
Locked
Morgan Stanley:
Locked
➜
Locked
|
Aug 07 2026 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
